These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 32171288)
1. Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies. Sheng X; Jin J; He Z; Huang Y; Zhou A; Wang J; Ren X; Ye D; Zhang X; Qin S; Zhou F; Wang B; Guo J BMC Cancer; 2020 Mar; 20(1):219. PubMed ID: 32171288 [TBL] [Abstract][Full Text] [Related]
2. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. Guo J; Jin J; Oya M; Uemura H; Takahashi S; Tatsugami K; Rha SY; Lee JL; Chung J; Lim HY; Wu HC; Chang YH; Azad A; Davis ID; Carrasco-Alfonso MJ; Nanua B; Han J; Ahmad Q; Motzer R J Hematol Oncol; 2018 May; 11(1):69. PubMed ID: 29788981 [TBL] [Abstract][Full Text] [Related]
3. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Sternberg CN; Motzer RJ; Hutson TE; Choueiri TK; Kollmannsberger C; Bjarnason GA; Paul Nathan ; Porta C; Grünwald V; Dezzani L; Han J; Tannir NM Clin Genitourin Cancer; 2019 Dec; 17(6):425-435.e4. PubMed ID: 31601514 [TBL] [Abstract][Full Text] [Related]
4. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). Lara PN; Villanueva L; Ibanez C; Erman M; Lee JL; Heinrich D; Lipatov ON; Gedye C; Gokmen E; Acevedo A; Semenov A; Park SH; Gafanov RA; Kose F; Jones M; Du X; Munteanu M; Perini R; Choueiri TK; Motzer RJ BMC Cancer; 2024 Jul; 23(Suppl 1):1253. PubMed ID: 39054430 [TBL] [Abstract][Full Text] [Related]
5. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216 [TBL] [Abstract][Full Text] [Related]
8. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States. Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772 [TBL] [Abstract][Full Text] [Related]
10. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma? Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763 [TBL] [Abstract][Full Text] [Related]
11. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Kim JH; Park I; Lee JL Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial. Xie M; He CS; Huang JK; Lin QZ Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828 [TBL] [Abstract][Full Text] [Related]
13. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. Köstek O; Yılmaz E; Hacıoğlu MB; Demircan NC; Gökyer A; Uzunoğlu S; Tunçbilek N; Çiçin İ; Erdoğan B Cancer Chemother Pharmacol; 2019 Apr; 83(4):735-742. PubMed ID: 30680522 [TBL] [Abstract][Full Text] [Related]
14. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience. Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028 [TBL] [Abstract][Full Text] [Related]
15. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823 [TBL] [Abstract][Full Text] [Related]
16. A Phase 4 Study of Everolimus to Evaluate Efficacy and Safety in Patients with Metastatic Renal-Cell Carcinoma after Failure of First-Line Sunitinib or Pazopanib (SUNPAZ). Schostak M; de Geeter P; Decker T; Resch A; Quiering C; Schmitz S Urol Int; 2020; 104(3-4):263-268. PubMed ID: 31726458 [TBL] [Abstract][Full Text] [Related]
17. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Beaumont JL; Salsman JM; Diaz J; Deen KC; McCann L; Powles T; Hackshaw MD; Motzer RJ; Cella D Cancer; 2016 Apr; 122(7):1108-15. PubMed ID: 27000445 [TBL] [Abstract][Full Text] [Related]
18. Anlotinib Versus Sunitinib as First-Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial. Zhou AP; Bai Y; Song Y; Luo H; Ren XB; Wang X; Shi B; Fu C; Cheng Y; Liu J; Qin S; Li J; Li H; Bai X; Ye D; Wang J; Ma J Oncologist; 2019 Aug; 24(8):e702-e708. PubMed ID: 30902918 [TBL] [Abstract][Full Text] [Related]
19. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293 [TBL] [Abstract][Full Text] [Related]
20. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis. Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]